Response to Conventional Therapy and Targeted Molecular Therapy

摘要: Currently, the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) involves platinum-based anticancer drugs such as cisplatin, which functions by formation of bulky platinum DNA adducts, along with a third-generation agent paclitaxel, gemcitabine, vinorelbine, or irinotecan.1, 2, 3, 4 Nonplatinum agents docetaxel, taxane that disrupting microtubule dynamics via β-tubulin binding, are also frequently used to treat NSCLC patients.4,5 Vinorelbine, vinca alkaloid, have been some success in treating patients.1 The benefits these systemic chemotherapeutic is limited patients advanced NSCLC, half those exhibiting an 8- 11-month median survival despite cisplatinbased therapy.2,6 Along troubling cisplatin toxicity, development resistance has become serious concern.1,3